secwatch.observer — SEC 8-K summary
======================================

Issuer:     C4 Therapeutics, Inc. (CCCC)
CIK:        0001662579
Form:       8-K
Filed at:   2025-01-14T23:59:59+00:00
Accession:  0001628280-25-001433
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

C4 Therapeutics unveils 2025 milestones; cash runway extended into 2027
-----------------------------------------------------------------------

- Cash, cash equivalents and marketable securities as of Dec 31, 2024 expected to fund operations into 2027.
- Cemsidomide Phase 1 dose escalation in multiple myeloma and NHL to complete in 2H 2025; next-phase studies to start early 2026.
- CFT1946 monotherapy dose escalation in BRAF V600 solid tumors to complete 1H 2025; Phase 1 data in melanoma and CRC expected 2H 2025.
- CFT8919 Phase 1 data from partner Betta in China will inform future development outside China.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1662579/000162828025001433/0001628280-25-001433-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1662579/000162828025001433/cccc-20250114.htm
  HTML page:      https://secwatch.observer/filing/0001628280-25-001433

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer